The FOXP1 gene has been identified as a new member of the winged helix family of transcription factors that have important roles in cellular transformation, differentiation and proliferation. In this study, we examined the expression of FOXP1 in the normal and malignant endometrium (stage I endometrioid adenocarcinoma cases), showing a frequent deregulation of its expression in cancer. Proliferative endometrium showed predominantly nuclear localization of FOXP1, while exclusively weak cytoplasmic staining was present in the secretory phase. Loss of nuclear expression was the most striking event in endometrial adenocarcinoma. Nuclear expression ranged from 0 to 20% (median 0%). Cytoplasmic expression was noted more frequently, ranging from 0 to 90% of cancer cells (median 30%). Overall, 24/82 cases (29.3%) were observed to lack both nuclear and cytoplasmic FOXP1 expression. Tumors with exclusively cytoplasmic expression of FOXP1 were linked with deep myometrial invasion and hypoxia-inducible factors 1a (HIF-1a) expression. On the other hand, the presence of nuclear FOXP1 expression was significantly linked with ER-a reactivity. Survival analysis did not reveal significant differences among patients grouped by FOXP1 expression, presumably due to the high curability of stage I disease. This study provides evidence on pathways to be investigated to elucidate the interplay between FOXP1, ER-a and HIF-1a in hormone dependent cancers.
Allelic deletions or imbalance are frequent in endometrial cancer, the 3p chromosome arm being involved most commonly. 1 In a study by Arlt et al, 2 loss of heterozygosity (LOH) at one or more loci on chromosome 3p was evident in 17% of endometrial carcinomas. Jones et al, 3 using CA-repeat polymorphisms, identified a common region of deletion at chromosome 3p12-21.1 in endometrial cancer.
Recently, the FOXP1 gene on chromosome 3p14. 1, 4 has been identified as a new member of the winged helix family of transcription factors that have important roles in cellular transformation, differentiation and proliferation (reviewed in Carlson and Mahlapuu 5 ). The FOXP1 protein is widely expressed in normal tissues, exhibiting a predominantly nuclear localization, while loss of expression or cytoplasmic mislocalization commonly characterizes malignant tissues. 4 Although the role of this protein in human cancer development and progression remains obscure, recent clinicopathological studies reported an important role in B-cell lymphomas. [6] [7] [8] A role for FOXP1 as a tumor suppressor gene in the development of breast cancer has been also suggested. 9 Studies of FOXP1 knockout mice have recently demonstrated that this molecule plays an essential role in development and that its deletion results in an embryonic lethal phenotype Interestingly, a loss of FOXP1 expression in cardiac myocytes results in their increased proliferation while loss of FOXP1 in cushion mesenchyme of heart outflow tracts was associated with decreased apoptosis, both observations are consistent with a role for FOXP1 as a tumor suppressor gene where loss of expression could potentially increase proliferation and reduce programmed cell death. 11 In this study, we examined the expression of FOXP1 in the normal and malignant endometrium, showing a frequent deregulation of its expression in cancer. Association of FOXP1 expression patterns with histopathological and other tumor-related features, including the presence of hormone receptors and the expression of endogenous markers of hypoxia and angiogenesis, were also examined.
Materials and methods
Formalin-fixed, paraffin-embedded tissues from 25 normal endometria at various phases of the menstrual cycle and 82 endometrial adenocarcinomas of the endometrioid cell type, stage I, were retrieved from the files of the Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece.
The histologically normal endometria were obtained from premenopausal women, age 34-40 years, who had undergone hysterectomy for nonendometrial disease. None of the patients had received hormone therapy. The normal endometria had been 'dated' on hematoxylin-and eosin-stained sections by using the histological criteria of Noyes et al.
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All cancer patients had been treated surgically with total abdominal hysterectomy and bilateral salpingo-oophorectomy. No lymph node sampling of the iliac nodes was performed. Histologic typing and grading of the endometrial tumors (grade 1 vs grade 2 and 3) and the depth of myometrial invasion were assessed on hematoxylin-eosin sections, using standard criteria. 13, 14 The follow-up of patients alive ranged from 22 to 182 months with a median of 70 months. At the time of analysis ten patients (12.2%) were dead with disease.
Immunohistochemistry for FOXP1
The FOXP1 protein was detected using the mouse JC12 monoclonal antibody (MoAb) (IgG2a MoAb; dilution 1:40). 4 Sections were deparaffinized and peroxidase was quenched with methanol and 3% H 2 O 2 for 15 min. Microwaving for antigen retrieval was used (3 Â 5 min). The primary antibodies were applied overnight. Following washing with TBS, sections were incubated with a secondary rabbit antimouse antibody (Kwik Biotinylated Secondary, 0.69A Shandon-Upshaw) for 15 min and washed in TBS. Kwik Streptavidin peroxidase reagent (039A Shandon-Upshaw) was applied for 15 min and sections were again washed in TBS. The color was developed by 15 min incubation with DAB solution and sections were weakly counterstained with hematoxylin.
Normal breast tissue sections with strong nuclear FOXP1 expression were used as positive controls. 9 Normal mouse immunoglobulin-G was substituted for primary antibody at the same concentration as a negative control.
FOXP1 expression was both cytoplasmic and nuclear in normal tissues. The extent and pattern of staining also varied among tumors. The percentage of cancer cells with FOXP1 nuclear reactivity was recorded in all optical fields and the mean value was used to form a final score. Similarly, the percentage of cancer cells with strong cytoplasmic staining was recorded in all optical fields and the mean value was used to characterize the case as for the cytoplasmic reactivity.
Immunohistochemistry for Other Antigens
Sections were cut at 3 mm and stained immunohistochemically with the following techniques: (a) a standard streptavidin-biotin method for the detection of estrogen receptor alpha (ER-a), progesterone receptor (PgR), hypoxia-inducible factors 1a (HIF-1a) and 2a (HIF-2a) and (b) the alkaline phosphatase/antialkaline phosphatase (APAAP) method for vessel staining (anti-CD31 MoAb) and the detection of the vascular endothelial growth factor (VEGF). [15] [16] [17] [18] Details of the primary antibodies, the working dilutions and the antigen retrieval methods used are given in Table 1 . MW ¼ microwave heating.
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Known positive controls were included in each staining run. Omission of the primary antibody and substitution by nonspecific immunoglobulin at the same concentration were used as negative controls.
Staining Patterns and Evaluation of Other Proteins
HIF-1a and HIF-2a are endogenous markers of hypoxia, exhibiting expression with a mixed nuclear and cytoplasmic pattern. Although nuclear presence of HIF is in accordance with the HIF activity in the nucleus, HIF protein is synthesized and degraded in the cytoplasm. Cytoplasmic expression, just like nuclear, is a tumor-specific feature and either expression pattern definitely indicate a selective HIF up-regulation. Redistribution of HIF subcellular localization during tissue collection is extremely difficult to control, and omission of the cytoplasmic pattern results in erroneous grouping of cases. Analysis based on purely nuclear expression showed an absence of, or a very marginal, statistical association with other molecular factors or prognosis in several previous studies, indicating that it is the tumor-specific finding of strong cytoplasmic HIF expression that should also be recorded to analyze upregulation of the HIF pathway in paraffinembedded material. The importance of assessing both cytoplasmic and nuclear staining for the expression of HIFs has been raised in earlier studies. 19, 20 A grading system reported in Table 2 , that groups cases using both expression patterns, has been proposed and applied in a series of previous studies by our group. 15, [21] [22] [23] The percentage of tumor cells expressing the various antigens under investigation was assessed semiquantitatively at Â 200 magnification. The counts were performed on the entire tumor area in all available fields of view. The mean value was used as a cut-off point to define cases of high and low tumor reactivity for VEGF cytoplasmic reactivity. For ER-a and PgR nuclear reactivity a cut-off point of 10% was used to define groups of high vs groups of low receptor expression.
Tumor angiogenesis was assessed by microvessel counting. Three areas of high vascular density (hot spots) were selected at the invading tumor front; the final microvessel score was the mean of the vessel counts obtained from these fields. Only blood vessels with a clearly defined lumen or a linear vessel shape, but not single endothelial cells, were taken into account.
In all cases, the assessment of vascular density was performed independently by two pathologists (AG, ES), having no access to the patient data. Discrepancies were resolved over the conference microscope.
Statistical Analysis
Statistical analysis and graphs were performed using the Instat 3.1 Package. and GraphPad Prism 2.01 package (GraphPad Software Inc., USA). A Fisher's exact test or Yate's continuity-corrected t-test was used for testing relationships between noncontinuous categorical (contingency tables). Linear regression analysis was used to assess correlation between continuous variables. Survival curves were plotted using the method of Kaplan and Meier, and the log-rank test was used to determine statistical differences between life tables. A P-valueo0.05 was considered significant.
Results

Expression Patterns of FOXP1 in Normal Endometrium
Proliferative endometrium showed predominantly nuclear localization of FOXP1, while exclusively weak cytoplasmic staining was present in the secretory phase (Figure 1a, b) . Stroma cells were negative. Expression of ER-a showed similar patterns of staining with nuclear localization during the proliferative phase and loss of nuclear expression during the secretory phase.
Expression Patterns of FOXP1 in Malignant Endometrium
The expression patterns of FOXP1 in cancer cells, when present, ranged from exclusively cytoplasmic to mixed nuclear/cytoplasmic, while solely nuclear staining was not noted. Loss of nuclear expression was the most striking event. Nuclear expression ranged from 0 to 20% (median 0%). Cytoplasmic expression was noted more frequently, ranging from 0 to 90% of cancer cells (median 30%). Overall, 24/ 82 cases (29.3%) were observed to lack both nuclear and cytoplasmic FOXP1 expression. Table 3 shows the distribution of cases according to the subcellular pattern of FOXP1 expression. Figure 1 shows the patterns of FOXP1 expression in malignant endometrium. Table 4 shows the association of FOXP1 expression patterns with histological and molecular variables. High FOXP1 nuclear expression was significantly linked with ER-a positivity (P ¼ 0.002) and marginally with PgR (P ¼ 0.08). Cytoplasmic expression was significantly linked with HIF-1a overexpression (P ¼ 0.01), with deep myometrial invasion (P ¼ 0.02) and marginally with poor differentiation (P ¼ 0.06) and HIF-2a reactivity (P ¼ 0.09). Linear regression analysis of nuclear FOXP1 and ER-a expression showed a significant association (P ¼ 0.003; r ¼ 0.35). Analysis of cytoplasmic FOXP1 expression and HIF-1a reactivity showed a significant association (P ¼ 0.007, r ¼ 0.30). The above findings strongly suggest that the nuclear vs cytoplasmic distribution of FOXP1 fluctuates during the menstrual cycle and that its subcellular localization may also play a distinct role in the pathology of endometrial cancer. As nuclear expression is the feature characterizing normal proliferative endometrium, an exclusively cytoplasmic localization may be important in cancer cell biology. For this reason we further analyzed cases to dissect three groups of carcinomas on the basis of FOXP1 expression patterns: (i) tumors that maintained nuclear FOXP1 localization in more than 10% of cancer cells; (ii) tumors that lost nuclear expression but maintained FOXP1 extensive cytoplasmic reactivity in 450% of cancer cells; and (iii) tumors with absence or low FOXP1 reactivity (in the nuclei of less than 10% of cancer cells or the cytoplasm of less than 50% of cancer cells). The association of this grouping of cases with histological and molecular variables is shown in Table 5 . This analysis clearly shows that tumors with exclusively cytoplasmic expression of FOXP1 were linked with deep myometrial invasion and HIF-1a expression. On the other hand, the presence of nuclear FOXP1 expression was significantly linked with ER-a reactivity, while loss of ER-a expression was a frequent event in cases with FOXP1 expression in the cytoplasm or loss of FOXP1 expression.
Correlation with Histological and Molecular Variables
Survival Analysis
Kaplan-Meier survival curves stratified for FOXP1 nuclear expression, FOXP1 cytoplasmic expression and combined nuclear/cytoplasmic patterns of expression are shown in Figure 2a -c, respectively. No significant association with survival was noted.
Discussion
In this study, we examined the expression of the FOXP1 transcription factor, a member of the forkhead/winged helix family of proteins, in normal and malignant endometrium. The JC12 MoAb used was previously shown not to recognize the closely related FOXP2, FOXP3 and FOXP4 proteins. 9 As expected from previous immunohistochemical studies showing a wide expression of the protein in normal tissues, FOXP1 was expressed in the nuclei and cytoplasm of normal cycling endometrium. The nuclear staining prevailing in the proliferative, estrogen dependent, phase of the menstrual cycle was absent during the secretory phase.
A striking loss of FOXP1 expression in malignant endometrium was noted, with 40% of cases exhibiting total lack of reactivity with the JC12 MoAb. Extensive cytoplasmic FOXP1 expression was recorded in 33% of cases, but approximately half of them lacked nuclear FOXP1 expression. In the remaining cancer cases, only limited nuclear or cytoplasmic expression was observed. This is particularly significant because malignant tissue is not typically characterized as hormonally regulated in a cyclic manner and endometrial adenocarcinoma displays an expression profile closer to normal proliferative than that of normal secretory endometrium. 24 The mechanism of this loss of FOXP1 expression is unknown. Several studies have reported allelic deletions of the 3p chromosome arm in endometrial cancer. [1] [2] [3] As the FOXP1 gene resides in the 3p14.1 position, deletion or chromosomic imbalance of this region may contribute to the loss of FOXP1 expression in endometrial cancer. However, a preliminary study of a small number of cases by fluorescent in situ hybridization (FISH), using FOXP1 gene probes, found that two cases which were negative for FOXP1 protein expression both gave dual FOXP1 FISH signals (AHB and Roland Ventura, unpublished data). Thus, in these cases, copy number changes did not appear to reflect the loss of FOXP1 expression.
Nuclear FOXP1 expression was associated significantly with the expression of ER-a and marginally with PgR expression as previously reported in breast cancer by Fox et al. 8 However, this group observed no direct regulation of FOXP1 expression levels by estrogen in experiments with the ERpositive MCF-7 cell line. This is interesting in the context of the fluctuations of FOXP1 expression in the normal endometrium, as these would normally indicate that its expression was hormonally regulated. Nevertheless, other members of the FOX family, such as FOXO3a/FKHRL-1, do regulate ER-a gene transcription and interact with ER-a in the presence of beta estradiol. [25] [26] [27] The biological importance of an association with nuclear FOXP1 expression and ER-a positivity is that the nuclear receptor box in the FOXP1 protein may also enable it to act as a coregulator of ER-a.
An interesting finding in the current work is the direct association of exclusively cytoplasmic expression of FOXP1 with HIF-1a overexpression. Nuclear/cytoplasmic shuttling of members of the forkhead protein family (ie FOXO1) has been reported to occur as a result of protein phosphorylation. 28 Phosphorylation of FKHRL1 via a phosphatidylinositol 3-kinase/Akt kinase results in cytoplasmic shuttling of the protein, 29 which suggests that similar mechanisms may be also involved in FOXP1 cytoplasmic localization. Given that hypoxia both enhances Act activity 30 and induces HIF-1a and -2a overexpression, the significant association between the cytoplasmic localization of FOXP1 and HIF-1a overexpression may be the result of a single cause, namely hypoxia. Several studies also suggested that Act significantly contributes to HIF-1a stabilization. 31, 32 A direct role of FOXP1 in HIF regulation cannot however, be excluded as a recent study indicated that the nuclear FOXO4 protein downregulates HIF-1a through prolyl hydroxylase/pVHL-independent transcriptional pathway. 33 The biological consequences of the cytoplasmic localization of FOXP1 or its overall loss of expression are obscure. The ability of FOXP1 to interact with other proteins, which may then be functionally removed from the nucleus through interaction with cytoplasmic FOXP1, provides one possible explanation as to why tumors with cytoplasmic expression might differ biologically from those that are FOXP1 negative. Apart from HIF-1a overexpression, the cytoplasmic FOXP1 expression pattern was linked with deep myometrial invasion and with poor differentiation, although this latter finding did not reach a level of statistical significance, probably because of the low number of cases analyzed. Despite the lack of any important prognostic association, survival curves revealed that loss of the FOXP1 protein confers a slightly worse outcome even in this highly curable stage of the disease. The associations with ER and prognosis are similar to those found in the study of Fox et al 9 in breast cancer. Abrogation of the FOXP1 suppressor activity may release a molecular cascade important for transformation and tumor progression. Although genes transcriptionally regulated by FOXP1 are unknown as yet, the herein reported association with HIF-1a overexpression and nuclear expression in proliferative endometrium certainly points towards a pathway related to tumor aggressiveness. The prognostic importance of FOXP1 loss of expression may have been revealed more effectively in advanced stages of the disease, where mortality is higher, but such cases were not included in our series. This study provides evidence on pathways to be investigated to elucidate the interplay between FOXP1, ER and HIF-1a in hormone-dependent cancers.
